Detalhe da pesquisa
1.
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.
Blood
; 137(3): 420-428, 2021 01 21.
Artigo
Inglês
| MEDLINE | ID: mdl-33475736
2.
Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.
Biol Blood Marrow Transplant
; 26(11): 2082-2088, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32745575
3.
Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy.
Biol Blood Marrow Transplant
; 25(11): 2211-2216, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31247313
4.
Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
Biol Blood Marrow Transplant
; 25(10): 2054-2060, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31173900
5.
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(3): 606-612, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30244109
6.
Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.
Biol Blood Marrow Transplant
; 24(6): 1237-1242, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29378303
7.
Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.
Biol Blood Marrow Transplant
; 24(4): 789-798, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29355721
8.
Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.
Blood
; 128(8): 1050-8, 2016 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-27297790
9.
Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.
Biol Blood Marrow Transplant
; 23(7): 1208-1214, 2017 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-28390985
10.
Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Biol Blood Marrow Transplant
; 23(12): 2192-2198, 2017 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-28864140
11.
Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Biol Blood Marrow Transplant
; 22(8): 1403-1409, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27095692
12.
T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.
Biol Blood Marrow Transplant
; 22(10): 1861-1866, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27375124
13.
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.
Biol Blood Marrow Transplant
; 22(10): 1816-1822, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27453362
14.
Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.
Biol Blood Marrow Transplant
; 22(1): 125-33, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-26359881
15.
Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Biol Blood Marrow Transplant
; 21(9): 1576-82, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25985915
16.
Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Biol Blood Marrow Transplant
; 21(7): 1299-307, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25797174
17.
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Haematologica
; 100(9): 1172-9, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26022709
18.
Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Biol Blood Marrow Transplant
; 20(11): 1828-34, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25064745
19.
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Blood
; 119(1): 55-63, 2012 Jan 05.
Artigo
Inglês
| MEDLINE | ID: mdl-22001391
20.
Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
Transplant Cell Ther
; 30(6): 607.e1-607.e8, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38552844